Literature DB >> 33572888

Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature.

Giacomo Santandrea1,2, Simonetta Piana2, Riccardo Valli2, Magda Zanelli2, Elisa Gasparini3, Antonio De Leo4, Vincenzo Dario Mandato5, Andrea Palicelli2.   

Abstract

The term "ovarian carcinoma" encompasses at least five different malignant neoplasms: high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, mucinous carcinoma, and clear cell carcinoma. These five histotypes demonstrated distinctive histological, molecular, and clinical features. The rise of novel target therapies and of a tailored oncological approach has demanded an integrated multidisciplinary approach in the setting of ovarian carcinoma. The need to implement a molecular-based classification in the worldwide diagnostic and therapeutic setting of ovarian cancer demanded a search for easy-to-use and cost-effective molecular-surrogate biomarkers, relying particularly on immunohistochemical analysis. The present review focuses on the role of immunohistochemistry as a surrogate of molecular analysis in the everyday diagnostic approach to ovarian carcinomas.

Entities:  

Keywords:  biomarkers; immunohistochemistry; molecular classification; ovarian cancer

Year:  2021        PMID： 33572888      PMCID： PMC7911119          DOI： 10.3390/diagnostics11020199

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN： 2075-4418


  106 in total

1.  Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.

Authors:  Iñigo Espinosa; Antonio De Leo; Emanuela D'Angelo; Juan M Rosa-Rosa; Marina Corominas; Alan Gonzalez; José Palacios; Jaime Prat
Journal:  Hum Pathol       Date:  2017-11-11       Impact factor: 3.466

2.  PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.

Authors:  Hao Chen; Kyle Molberg; Amanda L Strickland; Diego H Castrillon; Kelley Carrick; Qingping Jiang; Shuang Niu; Glorimar Rivera-Colon; Katja Gwin; Stacy Hinson; Jayanthi Lea; David S Miller; Wenxin Zheng; Elena Lucas
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.394

Review 3.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

4.  Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.

Authors:  Deborah DeLair; Esther Oliva; Martin Köbel; Antonio Macias; C Blake Gilks; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

5.  ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.

Authors:  C Luchini; F Bibeau; M J L Ligtenberg; N Singh; A Nottegar; T Bosse; R Miller; N Riaz; J-Y Douillard; F Andre; A Scarpa
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

Review 6.  Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review.

Authors:  Lorena Alves Teixeira; Francisco Jose Candido Dos Reis
Journal:  J Clin Pathol       Date:  2019-11-12       Impact factor: 3.411

7.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.

Authors:  Kyle C Strickland; Brooke E Howitt; Sachet A Shukla; Scott Rodig; Lauren L Ritterhouse; Joyce F Liu; Judy E Garber; Dipanjan Chowdhury; Catherine J Wu; Alan D D'Andrea; Ursula A Matulonis; Panagiotis A Konstantinopoulos
Journal:  Oncotarget       Date:  2016-03-22

8.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

9.  Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Authors:  Weiva Sieh; Martin Köbel; Teri A Longacre; David D Bowtell; Anna deFazio; Marc T Goodman; Estrid Høgdall; Suha Deen; Nicolas Wentzensen; Kirsten B Moysich; James D Brenton; Blaise A Clarke; Usha Menon; C Blake Gilks; Andre Kim; Jason Madore; Sian Fereday; Joshy George; Laura Galletta; Galina Lurie; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Rayna K Matsuno; Susanne Krüger Kjær; Allan Jensen; Claus Høgdall; Kimberly R Kalli; Brooke L Fridley; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Louise A Brinton; Hannah P Yang; Mark E Sherman; Montserrat García-Closas; Jolanta Lissowska; Kunle Odunsi; Carl Morrison; Shashikant Lele; Wiam Bshara; Lara Sucheston; Mercedes Jimenez-Linan; Kristy Driver; Jennifer Alsop; Marie Mack; Valerie McGuire; Joseph H Rothstein; Barry P Rosen; Marcus Q Bernardini; Helen Mackay; Amit Oza; Eva L Wozniak; Elizabeth Benjamin; Aleksandra Gentry-Maharaj; Simon A Gayther; Anna V Tinker; Leah M Prentice; Christine Chow; Michael S Anglesio; Sharon E Johnatty; Georgia Chenevix-Trench; Alice S Whittemore; Paul D P Pharoah; Ellen L Goode; David G Huntsman; Susan J Ramus
Journal:  Lancet Oncol       Date:  2013-07-09       Impact factor: 41.316

10.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Authors:  C Cruz; M Castroviejo-Bermejo; S Gutiérrez-Enríquez; A Llop-Guevara; Y H Ibrahim; A Gris-Oliver; S Bonache; B Morancho; A Bruna; O M Rueda; Z Lai; U M Polanska; G N Jones; P Kristel; L de Bustos; M Guzman; O Rodríguez; J Grueso; G Montalban; G Caratú; F Mancuso; R Fasani; J Jiménez; W J Howat; B Dougherty; A Vivancos; P Nuciforo; X Serres-Créixams; I T Rubio; A Oaknin; E Cadogan; J C Barrett; C Caldas; J Baselga; C Saura; J Cortés; J Arribas; J Jonkers; O Díez; M J O'Connor; J Balmaña; V Serra
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976
View more
  12 in total

1.  S-100 Immunohistochemical Positivity in Rhabdomyoma: An Underestimated Potential Diagnostic Pitfall in Routine Practice.

Authors:  Andrea Palicelli; Antonio Ramponi; Guido Valente; Renzo Boldorini; Annalisa Balbo Mussetto; Magda Zanelli
Journal:  Diagnostics (Basel)       Date:  2022-04-02

2.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

3.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Magda Zanelli; Maria Paola Bonasoni; Loredana De Marco; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Giacomo Santandrea; Maria Carolina Gelli; Alessandro Tafuni; Moira Ragazzi
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

4.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Valerio Copelli; Giuditta Bernardelli; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

Review 5.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Stefano Ascani; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Jatin Gandhi; Davide Nicoli; Enrico Farnetti; Simonetta Piana; Alessandro Tafuni; Martina Bonacini
Journal:  Biomedicines       Date:  2022-01-22

6.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Davide Nicoli; Enrico Farnetti; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

7.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Cristina Magi-Galluzzi; Sofia Cañete-Portillo; Alcides Chaux; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Daniel Athanazio; Jatin Gandhi; Alberto Cavazza; Giacomo Santandrea; Alessandro Tafuni; Magda Zanelli
Journal:  Cells       Date:  2021-11-14       Impact factor: 6.600

Review 8.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy.

Authors:  Andrea Palicelli; Martina Bonacini; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Stefano Ascani; Antonio De Leo; Jatin Gandhi; Alessandro Tafuni; Beatrice Melli
Journal:  J Pers Med       Date:  2021-12-06

Review 9.  The Evolution of Ovarian Carcinoma Subclassification.

Authors:  Martin Köbel; Eun Young Kang
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

10.  Relevance of ARID1A Mutations in Endometrial Carcinomas.

Authors:  Antonio De Leo; Gloria Ravegnini; Francesco Musiani; Thais Maloberti; Michela Visani; Viviana Sanza; Sabrina Angelini; Anna Myriam Perrone; Pierandrea De Iaco; Angelo Gianluca Corradini; Francesca Rosini; Marco Grillini; Donatella Santini; Claudio Ceccarelli; Claudio Zamagni; Giovanni Tallini; Dario de Biase
Journal:  Diagnostics (Basel)       Date:  2022-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.